Hemato Oncology Testing Market Size, Share, Future Challenges, Revenue, Demand, Opportunity, Analysis and Industry, Forecast 2025

1
Hemato Oncology Testing Market

• Size 2018, by Product (Service and Assay Kits),
  by Indication (Leukemia, Lymphoma, Other
  Cancers), Technology (NGS, PCR IHC, Cytogenetics,
  Others), End User (Hospitals, Laboratories,
  Academic Research Institutes, Others), Region
  and Forecast 2019 to 2025

Single Use License US 4400
Request Sample
2
Global Hemato Oncology Testing Market To Cross
USD 4.39 Billion By 2025

• The global hemato oncology testing market is
  anticipated to cross USD 4.39 billion by 2025,
  growing at a CAGR of over 13. Increasing
  prevalence of blood cancer amongst children is
  anticipated to drive the demand for test kits in
  the coming years.
• Adroit Market Research report on global hemato
  oncology testing market gives a holistic view of
  the market from 2015 to 2025, which includes
  factors such as market drivers, restraints,
  opportunities, challenges and regulatory
  scenario. The market has been studied for
  historic years from 2015 to 2017, with the base
  year of estimation as 2018 and forecast from 2019
  to 2025. The report covers the current status and
  future traits of the market at global as well as
  country level. In addition, the study also
  assesses the market competition with Porter's
  five forces analysis and positions the key
  players based on their product portfolio,
  geographic footprint, strategic initiatives and
  overall revenue. Prominent players operating in
  the global hemato oncology testing market have
  been studied in detail.
• According to the estimates of the Leukemia
  Lymphoma Society, during 2019, over 82,000 cases
  of lymphoma will be diagnosed alone in the U.S.,
  the country will also observe more than 8,000 and
  74,000 cases of Hodgkin Non-Hodgkin Lymphoma.
  With advancements in detection tests, the
  survival rate has escalated twice in past few
  years. High awareness rates coupled with NGOs
  working to make people knowledgeable about
  symptoms, the consumption of testing kits is
  likely to rise in coming years.
• In terms of product, services accounted for
  noticeable market share in 2018 and is
  anticipated to maintain its position compared to
  assay kits. Additionally, in terms of technology
  NGS is anticipated to emerge as the fastest
  growing segment compared to others.

3
Global Hemato Oncology Testing Market To Cross
USD 4.39 Billion By 2025

• In terms of geography, Asia Pacific is likely to
  emerge as the most promising regional market by
  2025. Easing of drug policies between India and
  china is likely to increase the trade of medical
  supplies within these countries this is
  anticipated to attract more companies to invest
  in the region. Such factors are likely to drive
  the Asia Pacific market in the coming years.
• Key vendors in the market include ARUP
  Laboratories Inc., Invivoscribe, Inc, Thermo
  Fisher Scientific, Inc, F. Hoffmann-La Roche Ltd,
  Abbott Laboratories, Adaptive Biotechnologies,
  ArcherDx, Inc., MolecularMD , etc. Increasing
  spending on RD by tier 1 companies has been a
  successful strategy for them in order to maintain
  their market position. For instance, Roche has
  been investing around 11-13 of their revenues
  in RD, also majority of the sales for the
  company has been from APAC. As a result of which,
  the company was successful in developing RealTime
  IDH1 and RealTime IDH2 PCR kits for rapid
  detection of the medical condition. Such
  strategies are anticipated to improve the rate of
  diagnosis and reduce the global economic burden
  of the disease in coming years.
• Browse the complete report on _at_
  https//www.adroitmarketresearch.com/industry-repo
  rts/hemato-oncology-testing-market

4
Segment Overview of Global hemato oncology
testing market

• Product Overview, 2015-2025 (USD Million)
• Services
• Assay Kits
• Indication Overview, 2015-2025 (USD Million)
• Leukemia
• Acute Myeloid Leukemia
• Acute Lymphocytic Leukemia
• Others
• Lymphoma
• Non-Hodgkin Lymphoma
• Hodgkin Lymphoma
• Others
• Technology Overview, 2015-2025 (USD Million)
• Cytogenetics.
• NGS
• PCR
• IHC

5
Segment Overview of Global hemato oncology
testing market

• End User Overview, 2015-2025 (USD Million)
• Hospitals
• Clinical Laboratories
• Academic Research Institutes
• Others
• Regional Overview, 2015-2025 (USD Million)
• North America
• Europe
• Asia Pacific
• Latin America
• Middle East Africa
• Purchase a single user copy of the global hemato
  oncology testing market report_at_
  https//www.adroitmarketresearch.com/researchrepor
  t/purchase/1512

6
About Us

• Adroit Market Research is an India-based business
  analytics and consulting company. Our target
  audience is a wide range of corporations,
  manufacturing companies, product/technology
  development institutions and industry
  associations that require understanding of a
  markets size, key trends, participants and
  future outlook of an industry. We intend to
  become our clients knowledge partner and provide
  them with valuable market insights to help create
  opportunities that increase their revenues. We
  follow a code Explore, Learn and Transform. At
  our core, we are curious people who love to
  identify and understand industry patterns, create
  an insightful study around our findings and churn
  out money-making roadmaps. Our analysts have
  tracked high growth markets in chemicals
  materials, healthcare pharmaceuticals,
  semiconductor electronics, energy power, food
  retail, consumer goods, technology, and
  machinery equipment sectors across the world to
  identify new opportunities, potential customers,
  prepare go-to-market (GTM) strategies, identify
  segments for revenue growth for companies, and
  many more.

• US Headquarters3131 McKinney Ave Ste 600
  Dallas, TX 75204 ,U.S.A 

• Phone [phone]
• Email sales_at_adroitmarketresearch.com